Personalized Medicine

The American College of Cardiology and American Heart Association have issued new guidelines on cholesterol screening and management, urging earlier testing and personalized risk assessments. The recommendations, presented on March 28 in New Orleans, emphasize lowering LDL cholesterol and incorporating genetic factors like lipoprotein(a). A new risk calculator aims to predict heart disease over longer periods.

15. mars 2026 Rapportert av AI Faktasjekket

University of Missouri researchers report that a small antibody fragment targeting the EphA2 protein can be tagged with a radioactive marker to make EphA2-positive tumors stand out on PET scans in mouse experiments, a step they say could help match patients to EphA2-targeted therapies.

MIT researchers have invented a swallowable pill that signals when medication is taken, aiming to combat poor adherence rates among patients. The device uses a biodegradable antenna to transmit a wireless confirmation shortly after ingestion. This innovation could benefit high-risk groups like organ transplant recipients and those with chronic infections.

5. januar 2026 Rapportert av AI

Researchers in Dresden have discovered that the protein MCL1, known for helping cancer cells evade death, also regulates their energy production through the mTOR pathway. This dual role explains why drugs targeting MCL1 can fight tumors but sometimes harm the heart. The team has developed a dietary approach to mitigate this cardiotoxicity, paving the way for safer therapies.

Scientists have identified a genetic modifier that helps cells cope with the loss of frataxin, the protein at the core of Friedreich’s ataxia. By lowering activity of the FDX2 gene, experiments in worms, human cells, and mice showed that key energy‑producing processes can be restored, pointing to a potential new treatment strategy.

13. desember 2025 Rapportert av AI Faktasjekket

In a recent open-access interview, Dr. Eric J. Nestler, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, looks back on nearly four decades of research into how stress and drugs reshape brain function. He highlights the transcription factor ΔFosB’s role in long-lasting behavioral change and argues that understanding natural resilience could shift mental health care toward strengthening protective mechanisms, not just correcting damage.